Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Imatinib is a standard long-term therapy for chronic myeloid leukemia (CML). Some people are able to stop taking imatinib after their CML is in remission, but sometimes it comes back and retreatment is needed. In this study, researchers want to see if adding the drug asciminib to imatinib therapy prior to a second attempt at stopping treatment will lead to prolonged treatment-free remission (no evidence of cancer after stopping therapy).
Researchers want to find the best dose of Debio 0123 that can be given with temozolomide to treat glioblastoma. Glioblastoma is a type of brain cancer. The people in this study have glioblastoma that keeps growing even after treatment.
Researchers want to find the best dose of iberdomide that can be given with elranatamab in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.
However, most cancer recurrences happen within the first year of treatment. Long-term ICI therapy can also cause lasting side effects and be expensive. Doctors are therefore interested in finding ways to identify which patients can stop maintenance therapy sooner.
Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient's own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
